Edition:
United States

Onxeo SA (C4X.PA)

C4X.PA on Paris Stock Exchange

1.22EUR
6:48am EDT
Change (% chg)

€0.01 (+0.75%)
Prev Close
€1.21
Open
€1.24
Day's High
€1.24
Day's Low
€1.22
Volume
46,770
Avg. Vol
143,413
52-wk High
€4.87
52-wk Low
€0.98

Latest Key Developments (Source: Significant Developments)

Onxeo Secures $7.5 Million Of Non-Dilutive Capital From Swk Holdings Corporation
Thursday, 7 Jun 2018 01:42am EDT 

June 7 (Reuters) - ONXEO SA ::ONXEO SECURES $7.5 MILLION OF NON-DILUTIVE CAPITAL FROM SWK HOLDINGS CORPORATION THROUGH SALE OF RIGHTS RELATED TO FUTURE BELEODAQ® ROYALTIES.PROCEEDS WILL BE FULLY ALLOCATED TO ADVANCEMENT OF ONXEO'S PIPELINE, INCLUDING ITS LEAD PRODUCT CANDIDATE, ASIDNA™.SALE OF BONDS ENTITLING SWK HOLDINGS CORPORATION TO RECEIVE $13.5 MILLION OF FUTURE ROYALTIES AND MILESTONES ON SALES OF BELEODAQ.SALES OF BONDS ENTITLING SWK HOLDINGS CORPORATION TO RECEIVE $13.5 MILLION OF FUTURE ROYALTIES, MILESTONES ON SALES OF BELEODAQ.  Full Article

Onxeo Presents Positive AsiDNA Preclinical Study Results
Thursday, 15 Mar 2018 02:04am EDT 

March 15 (Reuters) - ONXEO SA ::ANNOUNCES PRESENTATION OF TWO PRECLINICAL STUDY ABSTRACTS HIGHLIGHTING ASIDNA.WE BELIEVE ASIDNA HOLDS SIGNIFICANT PROMISE AS TREATMENT FOR SOLID TUMORS - CHIEF SCIENTIFIC OFFICER.ON ASIDNA AND HDAC INHIBITORS: RESULTS DEMONSTRATED THAT BELINOSTAT TREATMENT INDUCES DNA BREAK ACCUMULATION.ON ASIDNA AND HDAC INHIBITORS: RESULTS DEMONSTRATED THAT BELINOSTAT TREATMENT INDUCES GENETIC INSTABILITY IN TUMOR CELLS.ASIDNA INDUCED HIGH POTENTIATION OF BELINOSTAT ACTIVITY ON ITS TARGETS.RESULTS SUPPORT RATIONALE TO INVESTIGATE IN-VIVO ACTIVITY OF THIS COMBINATION IN DIFFERENT TUMOR TYPES.  Full Article

Onxeo ‍announces preclinical data for combination of AsiDNA™ and belinostat​
Thursday, 28 Sep 2017 02:01am EDT 

Sept 28 (Reuters) - ONXEO SA ::‍ANNOUNCES COMPELLING PRECLINICAL DATA IN COMBINATION FOR ITS TWO INNOVATIVE COMPOUNDS, ASIDNA™ AND BELINOSTAT​.‍RESULTS DEMONSTRATE VERY STRONG SYNERGISTIC EFFECT BETWEEN ASIDNA, FIRST-IN-CLASS DNA BREAK REPAIR INHIBITOR (DBRI), AND HISTONE DEACETYLASE INHIBITORS (HDACI)​.‍POTENTIAL APPLICATION OF ASIDNA™ IN COMBINATION WITH ANY HDACI FULLY COVERED BY KEY WORLDWIDE PATENT APPLICATION​.PARTICULARLY HIGH SYNERGY FOR COMBINATION OF ITS TWO PROPRIETORY ASSETS, ASIDNA AND BELINOSAT.HAS PLANNED AN EXTENSIVE PUBLICATION PLAN, STATING AT UPCOMING AACR MEETING IN APRIL 2018.​.  Full Article

Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics
Wednesday, 13 Sep 2017 02:01am EDT 

Sept 13 (Reuters) - ONXEO SA ::ONXEO GRANTS EXCLUSIVE WORLDWIDE LICENSE OF VALIDIVE DEVELOPED FOR THE TREATMENT OF ORAL SEVERE MUCOSITIS TO MONOPAR THERAPEUTICS.‍AGREEMENT INCLUDES SUBSTANTIAL MILESTONE PAYMENTS UP TO $108M AS WELL AS ESCALATING ROYALTIES ON FUTURE SALES​.‍MONOPAR THERAPEUTICS WILL DRIVE AND FUND ALL REMAINING DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES​.‍ONXEO IS ENTITLED TO AN IMMEDIATE $1.0M LICENSE FEE AND TO FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M SUBJECT TO ACHIEVEMENT OF AGREED UPON MILESTONES​.FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M SUBJECT TO ACHIEVEMENT OF AGREED UPON MILESTONES.‍ESCALATING ROYALTIES ON SALES UP TO A 2-DIGIT PERCENTAGE ARE ALSO PART OF AGREEMENT.​.FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M INCLUDING $15.5M RELATED TO REGULATORY MILESTONES, FROM PHASE III TO REGISTRATION.  Full Article

Onxeo divests two non-core products to Vectans Pharma
Monday, 31 Jul 2017 11:46am EDT 

July 31 (Reuters) - Onxeo Sa ::ONXEO DIVESTS TWO NON-CORE PRODUCTS IN ORAL PATHOLOGIES TO VECTANS PHARMA.WILL RECEIVE AN UPFRONT PAYMENT OF EUR 4 MILLION, AS WELL AS A POTENTIAL EARN-OUT PAYMENT.SALE OF TWO HISTORICAL PRODUCTS SITAVIG AND LORAMYC TO VECTANS PHARMA.TO ASSIGN TO VECTANS PHARMA ALL ASSETS RELATING TO TWO PRODUCTS - NOTABLY PATENTS, REGULATORY AUTHORIZATIONS AND OUTSTANDING CONTRACTS.  Full Article

Onxeo H1 net loss stable at 11.6‍​ million euros
Friday, 28 Jul 2017 01:02pm EDT 

July 28 (Reuters) - ONXEO SA ::H1 REVENUE EUR ‍​3.4 MILLION VERSUS EUR 1.9 MILLION YEAR AGO.H1 OPERATING LOSS EUR ‍​11.3 MILLION VERSUS LOSS OF 11.2 MILLION YEAR AGO.AT JUNE 30, 2017, THE COMPANY HAD CONSOLIDATED CASH POSITION OF €27.7 MILLION.H1 NET LOSS EUR 11.6‍​ MILLION VERSUS LOSS OF EUR 11.2 MILLION YEAR AGO.  Full Article

Onxeo launches capital increase by means of accelerated book-build offering
Monday, 19 Jun 2017 11:45am EDT 

June 19 (Reuters) - ONXEO SA : :ONXEO LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOK-BUILD OFFERING.GROSS PROCEEDS FROM THE TRANSACTION ARE EXPECTED TO BE APPROXIMATELY 12M€.  Full Article

Onxeo announces allowance of U.S. patent for Livatag in hepatocellular carcinoma
Wednesday, 10 May 2017 01:05pm EDT 

May 10 (Reuters) - ONXEO SA :ONXEO ANNOUNCES ALLOWANCE OF U.S. PATENT FOR LIVATAG® IN HEPATOCELLULAR CARCINOMA.USPTO NOTICE OF ALLOWANCE RECEIVED FOR PATENT RELATED TO SPECIFIC ROUTE OF ADMINISTRATION FOR LIVATAG PROVIDES PROTECTION OF RELATED CLAIMS UNTIL 2032.  Full Article

Onxeo Q1 revenue up 55 pct to 1.2 million euros
Wednesday, 26 Apr 2017 12:30pm EDT 

April 26 (Reuters) - Onxeo SA ::Q1 revenue up 55 pct to EUR 1.2 million ($1.3 million) .Cash position of EUR 21.7 million at March 31, 2017.  Full Article

Onxeo FY net loss widens to 22.7 million euros
Tuesday, 7 Mar 2017 12:50pm EST 

Onxeo SA : FY revenue EUR 4.4 million ($4.65 million) versus EUR 3.5 million year ago . FY operating loss of EUR 23.2 million versus loss of EUR 22.4 million year ago . FY net loss EUR 22.7 million versus loss of EUR 19.4 million year ago . Cash and cash equivalents of EUR 29.2 million at December 31, 2016 . Enrolment for the phase III Livatag study in advanced primary liver cancer completed on schedule to deliver preliminary results mid-2017 Further company coverage: [C4X.PA] ($1 = 0.9454 euros) (Gdynia Newsroom) ((gdynia.newsroom@thomsonreuters.com; +48 58 772 09 20;)).  Full Article

BRIEF-Onxeo Announces Start Of DRIIV Phase 1 Clinical Study Of AsiDNA

* ANNOUNCES START OF DRIIV, PHASE 1 CLINICAL STUDY OF ASIDNA IN ADVANCED SOLID TUMORS Source text for Eikon: Further company coverage: (Gdynia Newsroom)